Keros Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Keros Therapeutics sono diminuiti a un tasso medio annuo di -39.7%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 22.8%.

Informazioni chiave

-39.7%

Tasso di crescita degli utili

0.4%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	-22.8%
Rendimento del capitale proprio	-34.1%
Margine netto	-27,890.9%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Nov 20

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27

Keros Therapeutics prices equity offering at $50

Nov 13

Ripartizione dei ricavi e delle spese

Come Keros Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:KROS Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Sep 24	1	-182	39
30 Jun 24	0	-168	39
31 Mar 24	0	-160	37
31 Dec 23	0	-153	35
30 Sep 23	0	-142	33
30 Jun 23	0	-127	31
31 Mar 23	0	-116	29
31 Dec 22	0	-105	28
30 Sep 22	20	-82	26
30 Jun 22	20	-79	25
31 Mar 22	20	-67	23
31 Dec 21	20	-59	21
30 Sep 21	0	-61	19
30 Jun 21	0	-53	17
31 Mar 21	0	-49	15
31 Dec 20	0	-45	13
30 Sep 20	3	-39	10
30 Jun 20	5	-31	8
31 Mar 20	8	-23	5
31 Dec 19	10	-14	3
31 Dec 18	10	-2	2

Guadagni di qualità: KROS al momento non è redditizia.

Margine di profitto in crescita: KROS al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: KROS non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 39.7% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di KROS nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: KROS non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: KROS ha un Return on Equity negativo ( -34.08% ), in quanto al momento non è redditizio.

Keros Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

First half earnings released

Recent updates

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$158k worth of stock

Chief Scientific Officer exercised options and sold US$133k worth of stock

Keros Therapeutics, Inc. Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition

Chief Scientific Officer exercised options and sold US$527k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Consultant Claudia Ordonez has left the company

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Microcap Value Index

Keros Therapeutics, Inc. Announces Preliminary Results from Its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

Chief Scientific Officer notifies of intention to sell stock

Keros Therapeutics, Inc. Presents Data from the ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of KER-012

Chief Scientific Officer exercised options and sold US$132k worth of stock

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Chief Scientific Officer exercised options and sold US$316k worth of stock

Chief Scientific Officer exercised options and sold US$340k worth of stock

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Keros Therapeutics, Inc. Announces Results from Preclinical Studies of KER-050 and ALK2 Inhibitor Program

New 90-day low: US$55.25

Chief Scientific Officer notifies of intention to sell stock

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Keros Therapeutics, Inc. Announces Board Changes

New 90-day high: US$79.96

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

New 90-day high: US$68.02

Keros Therapeutics prices equity offering at $50

Keros Therapeutics, Inc. Receives Notice of Termination of the Collaboration Agreement from Novo Nordisk A/S